


Ro 08-2750

04/20

ALTERNATE NAMES: 7,10-dimethyl-2,4-dioxobenzo[g]pteridine-8-carbaldehyde; 7,10-dimethyl-2,4-dioxo-8-benzo[g]pteridinecarboxaldehyde; 2,3,4,10-Tetrahydro-7,10-dimethyl-2,4-dioxobenzo[g]pteridine-8-carboxaldehyde

CATALOG #: B3017-5 5 mg
B3017-25 25 mg

STRUCTURE:



MOLECULAR FORMULA: C₁₃H₁₀N₄O₃

MOLECULAR WEIGHT: 270.24

CAS NUMBER: 37854-59-4

APPEARANCE: Orange solid

PURITY: >95%

SOLUBILITY: ~2.7 mg/ml in DMSO

DESCRIPTION: Ro 08-2750 is an antagonist of nerve growth factor (NGF). It binds to the NGF dimer ($K_d \sim 1 \mu\text{M}$) and probably induces a change in its conformation such that NGF cannot bind to neurotrophin receptor p75(NTR). It inhibits NGF-induced cell death of SK-N-MC cells. It reverses NGF-induced decrease in β -catenin mRNA expression and decrease in migration of SKOV3 and OVCAR-3 ovarian cancer cells at a concentration 10 μM .

STORAGE TEMPERATURE: -20°C. Store in the dark. Product is light sensitive. Protect from air. Store under desiccating conditions.

HANDLING: Do not take internally. Wear gloves and mask when handling the product! Avoid contact by all modes of exposure.

REFERENCES:

1. Niederhauser, O., Mangold, M., Schubeneil, R., et al. NGF ligand alters NGF signaling via p75NTR and trkA. *J. Neurosci. Res.* 61(3), 263-272 (2000).
2. Li, B., Cai, S., Zhao, Y., et al. Nerve growth factor modulates the tumor cells migration in ovarian cancer through the WNT/ β -catenin pathway. *Oncotarget* 7(49), 81026-81048 (2016).

RELATED PRODUCTS:

NGF-beta, human recombinant (Cat. No. 4303)
 NGF-beta, human recombinant (Cat. No. 4303R)
 GW-441756 (Cat. No. B1147)
 Anti-Nerve Growth Factor Receptor Antibody (IHC637) (Cat. No. A1548)
 Noopept (Cat. No. B2148)

DISCLAIMER: ***FOR RESEARCH USE ONLY! Not to be used on humans.***